A Population Pharmacokinetic and Exposure-Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis.

Clin Pharmacokinet · 2026 · PMC12783266 · PMID 41212510

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

The exposure quartile analyses showed a clear trend of increase in the proportion of patients achieving vIGA-AD ® 0 or 1 at 16 weeks with increase in exposure.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.